spy003
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2025 (NCT06873724)
Timeline
Indications
Mechanism of action
- Interleukin-23 subunit alphaINHIBITOR
IL23A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07012395 | Phase 2 | May 27, 2025 | Spyre Therapeutics, Inc. |
| NCT06873724 | Phase 1 | Mar 10, 2025 | Altasciences Company Inc., Spyre Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2025 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1